BrainCheck’s Digital Cognitive Assessment Tool Validated in Peer-Reviewed Study
April 25, 2022 / Nueterra Capital Marketing
A peer-reviewed study published in the Journal of Medical Internet Research (JMIR) validates the comprehensive cognitive assessment and care management platform developed by BrainCheck, a Nueterra Capital portfolio company. In “A Computerized Cognitive Test Battery for Detection of Dementia and Mild Cognitive Impairment: Instrument Validation Study,” researchers found that BrainCheck achieved 88% or higher specificity in distinguishing dementia from normal cognition and mild cognitive impairment. As noted in a press release from the company, this study is one of the first to validate a digital tool for mild cognitive impairment (MCI). Although early detection of MCI is notoriously difficult, it plays an important role in creating successful interventions that can allow patients to live longer and healthier lives. You can read more about the study in Healio.